[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Russia Clinical Trial Market Opportunity Analysis

May 2013 | 66 pages | ID: R470DC9E6A1EN
Kuick Research

US$ 800.00

E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

The Russian clinical trial market accounts for a significant share in the global clinical trial market. The country has got the population and the prevalence of diseases which cater as a good pool of subjects for conducting the studies. The high quality of the regulations followed in the Russian market for clinical trials has led to better optimization of the studies. The Russian clinical trials market enjoys high speed of conducting studies owing to the high patient recruitment rates. The number of clinical trials conducted in Russia by foreign sponsors has tripled in the last decade. The quality of the clinical trials in Russia has been accepted by regulatory agencies such as the FDA and the EMA. The FDA inspection has rated Russia as having a standard quality of investigators leading to low deficiency rate. Russia has caught the attraction of big players in the pharmaceuticals industry, which has led to huge investments by these companies.

There has been an exponential rise in the clinical research services outsourced to Russia over in recent years. Despite the economic downturn, outsourcing trends in the field of clinical trials continue to be on a high in Russia. The value of the clinical trials market in Russia was around US$ 200 Million in 2012. Owing to various factors like a huge population base, easy patient recruitment and cheaper cost of trials, which are currently driving the market, it is expected that by 2016, the clinical trials market would surpass US$ 300 million mark.

“Russia Clinical Trial Market Opportunity Analysis” research report by KuicK Research is an intriguing text that gives detailed facts and analysis on latest developments in the Russia Clinical Trial Market. Report discusses various segments of the clinical trial market and analyzes the factors responsible for the growth and the need to resolve challenges to maintain growth momentum in future. Report discusses following aspects related to booming Clinical Trial Market in Russia:
  • Clinical Trial Market Overview
  • Growth Drivers & Challenges for Clinical Trial Market
  • Communicable & Non Communicable Disease Prevalence
  • Patient Recruitment Scenario
  • Regulations for Conducting Clinical Trial
  • Key CRO Operating in Market
1. RUSSIA CLINICAL TRIAL MARKET OVERVIEW

1.1 Market Overview
1.2 Factors Driving the Market
1.3 Challenges to be resolved

2. DISEASE PREVALENCE IN RUSSIA

2.1 Non-Communicable Diseases
2.2 Communicable Diseases

3. CLINICAL TRIAL MARKET BY SEGMENT

3.1 By Phase
3.2 By Therapeutic Area
3.3 By Domestic & International Sponsors

4. PATIENT RECRUITMENT & COST ANALYSIS

5. REGULATORY & POLICY FRAMEWORK

5.1 Rules for Import and Export of Biological Materials Obtained in Clinical Trials
5.2 Rules for Accreditation of Medical Institutions for the Right to Conduct Clinical Trials
5.3 Compulsory Insurance of Patient Involved in Clinical Trials
5.4 Procedure of Import of Medicines

6. KEY CRO

6.1 Synergy Research Group
6.2 Cromos Pharma
6.3 OCT
6.4 MatrixPharm
6.5 CONGENIX
6.6 Parexel
6.7 Global Clinical Trials
6.8 Quintiles

LIST OF FIGURES

Figure 1-1: Clinical Trial Market (US$ Million), 2012-2018
Figure 1-2: Clinical Trials Market by Type of Sponsors, 2012
Figure 1-3: Factors Driving the Growth of the Clinical Trial Market
Figure 2-1: Share Communicable & Non-Communicable Diseases, 2012
Figure 3-1: Share of Clinical Trials Market by Phase (%), 2012
Figure 3-2: Number Clinical Trials Market by Phase, 2011 & 2012
Figure 3-3: Clinical Trials by Therapeutic Segment, 2012
Figure 3-4: Clinical Trials Market by Sponsoring Country, 2012
Figure 3-5: Number of Russian & International Sponsors, 2012
Figure 4-1: Trend of Patient Recruitment, 2011-2015
Figure 4-2: Patient Enrolment by Phase (%), 2012

Russia is the most populated country in the European region with a population of 144million. The country has 12 cities, where population is more than a million. The presenceof a significant population base makes Russia one of the most favored nations forconducting clinical trials. Russia boosts of a highly centralized healthcare system withmajority of the patients concentrated in specialized hospitals and large tertiary centres,which is ideal for clinical trial recruitment. Totally, there are 10,000 hospitals in Russia,with a high ratio of physicians to per 1000 patients. Consequently, the country hasrecorded high rates of clinical trial productivity (close to 10 times more than in the USA orthe EU regions).

Attributing to the new legislation introduced in September, 2010 (On Circulation ofMedicines, which requires the companies to conduct clinical trials in Russia prior toregistering their new drugs), the Russian clinical trials market is poised for significantgrowth. The combination of lower costs, lower regulatory hurdles, and increased publicand private investment drive the growth in the clinical trials industry in Russia.

The Russian clinical trial market accounts for a significant share in the global pie ofclinical trial market. The country has got the population and the prevalence of diseaseswhich cater as a good pool of subjects for conducting the studies. The high quality of theregulations followed in the Russian market for clinical trials has led to better optimizationof the studies. The Russian clinical trials market enjoys high speed of conducting studiesowing to the high patient recruitment rates. The number of clinical trials conducted inRussia by foreign sponsors has tripled in the last decade. The quality of the clinical trialsin Russia has been accepted by regulatory agencies such as the FDA and the EMA. 



More Publications